AOR is a Canadian natural health product company, and this is one particular product that theyve pioneered and supporting research in Canada for, as you mentioned, preterm babies and the application, thats just the tip of the iceberg
In Vitro GLP-1R agonist 2 (100 nM, 1,000 nM) activates GLP-1 receptor-mediated cAMP production, with an EC 50 of 101 nM, but exhibits a self-limiting effect at high concentrations [2]
Therefore, there is an urgent need for alternative therapeutic approaches, including plant-derived phytochemicals, that can directly modulate the core pathogenic mechanisms of PD, such as neuroinflammation, mitochondrial dysfunction and S aggregation
Furthermore, the efficiency of autophagosome-lysosome fusion represents a potential bottleneck in the recycling system, dependent on Rab7 activity and its facilitation of HOPS complex assembly